Re-defining innovation

Nouscom’s proprietary immunotherapy platforms utilize a portfolio of uniquely engineered viral vectors optimized for the efficient expression of long strings of tumor neoantigens and comprise a powerful toolkit for the induction of broad and potent anti-tumor T cell responses. The Company’s deep knowledge of vaccine manufacturing, and the platform’s capacity to reliably encode unprecedented numbers of neoantigens is combined with proprietary approaches to neoantigen identification. Our mission is to generate safe, innovative, and potent next-generation cancer immunotherapies that selectively eliminate tumor cells. Our published pre-clinical and clinical data indicate that our approach is able to induce strong immune responses with potential to expand the applicability and efficacy of existing immunotherapies while delivering high levels of safety and tolerability. (D’Alise et al, Nature Comm, 2019; D’Alise et al, Science Translational Medicine, 2022; Bechter et al, Cancer Res, 2023; Fakih et al, J. Clin Oncology, 2022; Leoni & D’Alise et al, Vaccines 2021; Leoni et al, Cancer Res, 2020).